Drug profile

The FDA adverse-event record for Medetomidine

97 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Medetomidine. See the species affected, top reactions, and outcomes below.

97
adverse-event reports
15.5%
death-coded share
Dog
most-reported species
14
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
97
Total Reports
15
Deaths Reported
15.5%
Death Rate

Active Ingredients

Medetomidine

Administration Routes

UnknownIntramuscularIntravenousParenteralOther

Species Affected

Dog 52
Cat 40
Rabbit 1
Other Bovine 1
Deer 1
Unknown 1
Other 1

Most Affected Breeds

Domestic Shorthair 22
Retriever - Labrador 6
Pug 6
Cat (unknown) 5
Dog (unknown) 5
Boxer (German Boxer) 4
Unknown 4
Beagle 3
Domestic Mediumhair 3
Retriever - Golden 2

Most Reported Reactions

Lack of efficacy - NOS 14
Anorexia 11
Lethargy (see also Central nervous system depression in 'Neurological') 10
Injection site swelling 10
Vomiting 9
Elevated blood urea nitrogen (BUN) 9
Death 9
Other abnormal test result NOS 8
Not eating 8
Hypothermia 7
Tachycardia 7
Weight loss 7

Outcome Breakdown

Recovered/Normal
32 (33.3%)
Outcome Unknown
31 (32.3%)
Ongoing
17 (17.7%)
Died
10 (10.4%)
Euthanized
5 (5.2%)
Recovered with Sequela
1 (1.0%)

Medetomidine Adverse Event Insights

97 reports name Medetomidine; 15 recorded a death outcome (15.5% of reported events, not a population-level mortality rate). Active ingredient: Medetomidine. Administration routes: Unknown, Intramuscular, Intravenous, Parenteral.

By species: Dog (52 reports), Cat (40 reports), Rabbit (1 reports). By breed: Domestic Shorthair (22), Retriever - Labrador (6), Pug (6).

Leading clinical signs: Lack of efficacy - NOS (14), Anorexia (11), Lethargy (see also Central nervous system depression in 'Neurological') (10), Injection site swelling (10). Outcome, 96 coded reports: Recovered/Normal leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.